Ipilimumab With Carboplatin and Paclitaxel in Patients With Unresectable Stage III and Stage IV Melanoma

Phase 2 Unknown 30 enrolled Jewish General Hospital

RandomizedParallel-groupOpen-labelTreatment

Summary

The safety of the combination of ipilimumab with carboplatin/paclitaxel treatment with two different dosing schedules will be investigated in patients with metastatic melanoma. This protocol will also investigate both the clinical benefit of this combination and the features of the host immune system that may predict response to ipilimumab with chemotherapy in patients with unresectable Stage III and Stage IV melanoma.

Timeline

Start: 2012-11
Primary completion: 2017-02
Completion: 2026-05

Publications

Jamal R, Lapointe R, Cocolakis E, Thebault P, Kazemi S, Friedmann JE, Dionne J, Cailhier JF, Belanger K, Ayoub JP, Le H, Lambert C, El-Hajjar J, van Kempen LC, Spatz A, Miller WH Jr. Peripheral and local predictive immune signatures identified in a phase II trial of ipilimumab with carboplatin/paclitaxel in unresectable stage III or stage IV melanoma. J Immunother Cancer. 2017 Nov 21;5(1):83. doi: 10.1186/s40425-017-0290-x.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Carboplatin	Small molecule	—	—
Subject	Ipilimumab	Monoclonal antibody	3 mg/kg	—
Subject	Paclitaxel	Small molecule	175 mg/m2	—

Indications

No indication recorded.